

AMOÉBA announces efficacy results of more than 90% for *Willaertia magna* *C2c Maky* on vine mildew

Lyon, 4th Mai 2018 - AMOÉBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating the risk of waterborne bacteria, announces today the first greenhouse test results conducted with the microorganism, *Willaertia magna C2c Maky*, used as a biocontrol agent for the control of mildew on grapevine.

The results of the first greenhouse trials show very clear dose-responses of *Willaertia magna C2c Maky* in a formulated product. The efficacy of more than 90% of the formulated product on mildew has to be compared to the usual efficacy of biocontrol agents of around 50% observed in greenhouses.

A new series of tests is scheduled in 2018 in preparation of the field trials planned in 2019.

These first greenhouse tests, which confirm the previous *in vitro* trials (see our press release dated November 22, 2017), are a fundamental milestone to validate the potential use of *Willaertia magna C2c Maky* as an alternative to traditional chemical products.

These tests were carried out by CONIDIA, an independent recognized expert in fungi and their resistance to fungicides.

This milestone will enable the Company to start working on the regulatory dossier and to accelerate the discussions with the key market players in view of a potential partnership.

*«We consider the results of those first greenhouse tests as very promising on the basis of the efficacy usually reached with some biocontrol products of around 50% », states Sébastien VACHER, **Global Manager de CONIDIA**. « Those results were obtained in robust trial conditions, in line with the good practices for trials conducted for plant protection products. », added Sébastien VACHER.*

*« As mentioned by the French Institute for vine and grapevine (Institut Français de la Vigne et du Vin), the most effective biocontrol product only brings a rate of 20 to 30% efficacy in field trials. Our level of efficacy reaches 90% in greenhouses which would allow us, after validation of field trials, to offer a real alternative solution meeting the essential market needs. This is a key turning point for the global players to enable them to come forward as potential co-developer or partner with Amoéba. Thanks to this success, we are now targeting other crop diseases on crops (such as tomatoes, beetroots, potatoes,..) in order to broaden our portfolio », states Fabrice PLASSON, **CEO of AMOÉBA**.*



About AMOEBA:

Amoéba's ambition is to become the world leader in the treatment of waterborne bacterial risk, wound care and plant protection. Our BIOMEBA solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn¹⁾ on a global chemical biocide market for water treatment, evaluated at €21Bn⁽²⁾. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at €751 million⁽³⁾ in the USA, and the biocontrol market for plant protection estimated globally at €1.6Bn⁽⁴⁾. Sales of the BIOMEBA product for use in industrial cooling towers is subject to the Company being granted local regulatory market authorizations.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts :

Amoéba

Nathalie COMBROUSSE

Responsable Marketing Communication

04 81 09 18 15

nathalie.combrousse@amoeba-biocide.com

Actifin

Ghislaine GASPARETTO

Communication financière

01 56 88 11 11

ggasparetto@actifin.fr

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (*Autorité des Marchés Financiers*) on April 27, 2018 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.